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Background/Purpose: Metabolic syndrome (MS) is a cluster of diseases related to insulin resistance and is
an important cardiovascular risk factor. In addition, MS has been linked to some malignancies, including
colorectal cancer. Colon adenoma is a well-established pre-malignant lesion of colorectal cancer. The aim
of this study was to determine the effect of various components of MS on the risk of colorectal adenoma.
Methods: From October 2004 to April 2006, 3106 subjects who had undergone complete colonoscopy for
health examinations at the hospital were enrolled. MS was defined according to the modified National
Cholesterol Education Program Adult Treatment Panel III definition for South Asians and Chinese. Multivariate
logistic regression was used to analyze the association between components of MS and colorectal adenoma.
Results: Of the 3106 subjects, the mean age was 47.1 ± 10.8 years and there were 397 (13%) subjects with
pathologically proven colorectal adenoma. Male sex, old age (≥ 50 years), current smokers, and abdomi-
nal obesity were associated with increasing risk of colorectal adenoma. MS was associated with increased
risk of colorectal adenoma (odds ratio: 1.71, 95% confidence interval: 1.34–2.71), and this risk increased
with the number of metabolic components. Multiple and synchronous adenomas of the proximal and
distal colon were positively associated with MS.
Conclusion: Subjects with metabolic syndrome have increased risk of developing colorectal adenoma.
Screening colonoscopy for prevention of colorectal adenoma might be warranted when abdominal obesity
or more than three components of MS are present.
Key Words: abdominal obesity, colorectal adenoma, metabolic syndrome
©2011 Elsevier & Formosan Medical Association
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2Center for Environmental and Occupational Medicine, 3Division of Gastroenterology, Department of Internal Medicine, and
1Department of Family Medicine, Shin Kong Wu Ho-Su Memorial Hospital, 4School of Medicine, Fu Jen Catholic University,
Taipei, Taiwan.
Received: August 13, 2009
Revised: December 1, 2009
Accepted: March 19, 2010
*Correspondence to: Dr Yu-Hung Chen, Department of Family Medicine, Shin Kong Wu Ho-Su
Memorial Hospital, 95 Wen Chang Road, Shih Lin District, Taipei 111, Taiwan.
E-mail: m001064@ms.skh.org.tw
Metabolic syndrome (MS) is recognized as an im-
portant risk factor for cardiovascular disease.1,2 It
contributes to morbidity and mortality through its
main components, including diabetes mellitus,
obesity, dyslipidemia, and hypertension. The in-
cidence of MS has dramatically increased in devel-
oped countries as a result of obesity, which is the
main component of insulin resistance.3 However,
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current statistics show that Asian as well as west-
ern countries are showing increasing incidence
of obesity and MS, which might be caused by diet
and lifestyle westernization.4
Researchers speculate that some cancers share
several risk factors with cardiovascular diseases,
such as prostate, pancreas, and colorectal cancer.3,5
Colorectal cancer is an important health prob-
lem in developed countries and is the third lead-
ing cause of death from cancer in Taiwan.
Colorectal adenoma is now considered a precur-
sor of colonic adenocarcinoma through the well-
known adenoma–carcinoma sequence. It provides
the possibility for clinicians to interrupt the for-
mation of most colorectal cancers in early stages
through adequate screening and resection of the
adenomas. Epidemiological studies have shown
that most MS components have been linked 
in some way to the development of colorectal
cancer.6,7
The underlying mechanism has been widely
discussed and several studies have concluded
that it is the result of dysregulation of insulin
and insulin-like growth factors (IGFs), the so-
called IGF axis.8 Another hypothesis that links
MS and colorectal cancer is chronic inflam-
mation. Chiu et al have suggested that elevated 
C-reactive protein (CRP), a widely used marker
of inflammation, is associated with increased
risk of colorectal neoplasia in men.9 It appears
that such a relationship also exists between MS
and colorectal adenoma. Researchers have been
trying to seek the most adequate and highly cor-
related clinical predictor of insulin resistance
and chronic inflammation to determine the pop-
ulation that warrants colonoscopy screening.
However, studies that have suggested an associ-
ation between clinical manifestations of MS and
colorectal adenoma have shown considerable
heterogeneity.10,11
The present study focused on the associa-
tion between individual components of MS and
colorectal adenoma. Furthermore, we examined 
the effect of different combinations of the meta-
bolic components on the risk of colorectal 
adenoma.
Materials and Methods
Subjects
We enrolled a consecutive series of 3361 adult
subjects (≥ 20 years old) who underwent a vol-
untary, complete routine health check-up at Shin
Kong Wu Ho-Su Memorial Hospital from October
2004 to April 2006. Each participant was inter-
viewed by a physician and received a compre-
hensive physical examination. Detailed personal
histories, including hypertension, diabetes melli-
tus, current medication, and lifestyle characteris-
tics, such as smoking and alcohol consumption,
were collected. All the participants received an-
thropometric and blood biochemical tests, which
included fasting plasma glucose, serum triglyceride
and high-density lipoprotein (HDL)–cholesterol
level, and received total colonoscopy.
We excluded 110 subjects with findings that
were not histologically confirmed (aspirin use, too
small polyps, or not sufficiently well to undergo
polypectomy), 89 with incomplete colonoscopy
or poor results, five diagnosed with colorectal can-
cer, one with carcinoid tumor, two with a past his-
tory of inflammatory bowel disease, five with a
past history of colorectal cancer, and 43 with other
malignancies. Finally, 397 subjects with patho-
logically proven colorectal adenomas, such as tu-
bular, villous, or dysplastic adenoma were in the
case group, and 2709 subjects with normal find-
ings or non-neoplasia, such as hyperplastic polyps
or non-specific colitis were in the control group.
The hospital ethics committee approved this
study and all participants provided informed
consent. The institutional review board (IRB)
number of this study was 95E-056.
Definitions
According to the modified National Cholesterol
Education Program Adult Treatment Panel III
(NCEP ATP III) definition for South Asians and
Chinese, MS was defined if three or more of the
following criteria were satisfied: (1) abdominal
obesity, waist circumference ≥ 90 cm in men and
≥ 80 cm in women; (2) high blood pressure,
≥ 130 mmHg systolic, ≥ 85 mmHg diastolic, or
current medication for hypertension; (3) high
serum fasting glucose, ≥ 100 mg/dL or current use
of antidiabetic therapy; (4) low HDL–cholesterol
level, < 40 mg/dL in men and < 50 mg/dL in
women; and (5) hypertriglyceridemia ≥150mg/dL.
According to the World Health Organization guide
of physical measurements, waist circumference
was measured at the midpoint between the lower
part of the last rib and the top of the hip.
Subjects were classified as smokers or non-
smokers, whereas those who had quit smoking
for > 1 year were defined as ex-smokers. Subjects
who had an alcohol consumption of > 1 drink
per week were defined as drinkers.
Colonoscopy and polyp characteristics
Complete colonoscopy that reached at least the
cecum after bowel preparation with Polyethylene
glycol electrolytes (PES-ELS) (Klean-Prep®; Norgine,
Uxbridge, Middlesex, UK) and sodium phos-
phate (Fleet®, C.B. Fleet Company, Lynchburg,
VA, USA) were performed. Colonoscopy was per-
formed on each subject by one of the seven expe-
rienced colonoscopists who were blinded to the
metabolic status of the subjects.
The characteristics of the adenoma, including
location, number, size, and pathology report were
documented. The cecum, ascending colon, and
transverse colon were defined as proximal colon,
whereas the descending colon, sigmoid colon, and
rectum were defined as distal colon. The patho-
logical diagnosis and definition of colorectal
adenoma was based on the World Health Organi-
zation classification.12 Multiple adenomas were
defined as more than one, and the size of the
adenoma was classified into <0.5cm, 0.5–1.0cm,
and >1.0 cm. In cases with multiple adenomas, the
largest tumor was measured. All specimens were
diagnosed with histological descriptions by patho-
logists. Advanced adenoma was defined as tubular
adenoma ≥ 1 cm in diameter, or a polyp with vil-
lous histological features, or high-grade dysplasia.
Statistical analysis
Continuous variables were expressed as mean ±
standard deviation. Mean age and components of
MS were compared with a two-sample Student’s 
t test, and the χ2 test was used to compare cate-
gorical variables. Study subjects were categorized
according to: age (≥ 50 years vs. < 50 years); sex
(male vs. female); current smoker versus ex-smoker
versus non-smoker; drinker versus non-drinker;
with past history of colorectal adenoma versus
without; MS versus those without; abdominal obe-
sity versus those without; high blood pressure or
current medication for hypertension versus those
without; high serum fasting glucose or current use
of antidiabetic therapy versus those without; low
HDL–cholesterol level versus those without; and
hypertriglyceridemia versus those without. Mul-
tiple logistic regression included adjustment for
age, sex, smoking, alcohol drinking, and past his-
tory, and MS was used to examine the odds ratio
(OR) of those potential risk factors. In the analysis
of the association between individual compo-
nents of MS and colorectal adenoma, adjust-
ment for age, sex, smoking, drinking, past history,
and other MS components was included. The five
MS components were examined as covariates, to-
gether with other major risk factors. The interac-
tions between the variables were also assessed in
both models. In the analysis of the influence of
MS on the characteristics of colorectal adenoma,
age, sex, smoking, drinking, and past history were
adjusted. For each hazard, the OR and 95% confi-
dence interval (CI) were given. A p value <0.05 was
considered statistically significant. The x variable 
of Figure 1 was the number of MS components
listed numerically, while the y axis showed the
adjusted OR for colorectal adenoma. We subse-
quently analyzed the association between various
MS components and adenoma. Figure 2 shows
the prevalence of clusters of MS components clas-
sified by tree analysis. By comparison with the
average prevalence of colorectal adenoma in the
study population, participants were further di-
vided into average (10.6%), moderate (17.8%),
and high (31.3%) risk groups.
All statistical analyses were performed using
SAS for Windows version 9.1.3 (SAS institute
Inc., Cary, NC, USA) or SPSS version 17.0 (SPSS
Inc. Chicago, IL, USA).
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Results
A total of 3106 subjects were included and divided
into two groups: 397 subjects with pathologically
proven colorectal adenoma were assigned to the
case group, and 2709 subjects with normal find-
ings or non-neoplasia were assigned to the control
group. There were 1824 men (58%) and 1282
women (42%), with a mean age of 47.1 ± 10.8
years (range: 20–85 years). Demographic charac-
teristics and basic measurements, including age,
sex, smoking, drinking, past history of colorectal
adenoma, waist circumference, blood pressure,
fasting blood glucose, triglyceride, and HDL–
cholesterol are listed in Table 1.
Old age (≥ 50 years), male sex, current smokers
and positive past history were associated with 
increased risk of colorectal adenoma (Table 2).
Ex-smokers who had quit smoking for > 1 year
had a higher prevalence of developing colorectal
adenoma than never-smokers, but the effect on
colorectal adenoma was not significant. There
was no significant association between drinking
and colorectal adenoma. MS was associated with
an increased risk of colorectal adenoma (OR:
1.71, 95% CI: 1.34–2.17). Among the compo-
nents of MS, only abdominal obesity was signifi-
cantly associated with colorectal adenoma (OR:
1.64, 95% CI: 1.30–2.07) after adjusting for age,
Category
Adenoma
Control
Total 83.3 2586
89.4 2313
10.6 273
% N
OR = 1 OR = 1.84, p = 0.006
95% CI = 1.19–2.84
OR = 2.91, p < 0.001
95% CI = 2.10–4.03
Category
Adenoma
Control
Total 9.2 287
82.2 236
17.8 51
% N Category
Adenoma
Control
Total 7.5 233
68.7 160
31.3 73
% N
Overall population
Category
Adenoma
Control
Total 100 3106
87.2 2709
12.8 397
% N
Adenoma
Control
17 combinations
Average-risk* Moderate-risk* High-risk*
MS-neg;PTH
GTH;GPT;OGT
GPH;OTH;OPH
OPT;GPTH;OGTH
OGH;OGP;OGTH
OGPH;OGPT;OGPTH
Figure 2. Classification tree analysis between various combinations of metabolic syndrome components and prevalence
of colorectal adenoma. MS-neg: negative for metabolic syndrome; O: presence of abdominal obesity; G: presence of im-
paired fasting blood glucose; P: presence of elevated blood pressure; T: presence of high triglyceride level; H: presence
of low HDL–cholesterol level. *Various combinations of metabolic syndrome components by using the Chi-squared
Automatic Interaction Detector method. The p values are < 0.001 between each group.
Figure 1. Association between numbers of metabolic syn-
drome components and odds ratio of colorectal adenoma
after adjustments for age, sex, smoking, and past history
of colorectal adenoma. The baseline comparator group
were subjects without any metabolic syndrome component.
ap < 0.001.
1
1.14
1.38
1.61a
2.57a
3.23a
0
A
dj
us
te
d 
O
R
 o
f c
ol
or
ec
ta
l
ad
en
om
a
1
2
3
4
2 3
No. of metabolic syndrome components
4 5
N.C. Hu, et al
104 J Formos Med Assoc | 2011 • Vol 110 • No 2
sex, smoking, drinking, past history, and other
components of MS. The OR for colorectal ade-
noma increased with the number of metabolic
components from one to five, with ORs of 1.14,
1.38, 1.61, 2.57 and 3.23, respectively (Figure 1).
The p value was significant when three or more
components co-existed. In the “classification tree
analysis” of various combinations of MS compo-
nents by using the Chi-squared Automatic
Interaction Detector method (Figure 2), the p
values between each group were all statistically
significant. The ORs of moderate- and high-risk
groups compared with the average-risk group
were 1.84 (95% CI: 1.19–2.84) and 2.91 (95%
CI: 2.10–4.03), respectively. Although prevalence
of colorectal adenoma for various combinations of
MS components showed divergence, abdominal
obesity was the most consistent in the moderate-
and high-prevalence group. In the analysis of
adenoma characteristics, including location,
number, size, and pathology report (Table 3),
MS was significantly associated with multiple 
tumors (OR: 1.67, 95% CI: 1.08–2.59) and ade-
nomas located synchronously at the proximal
and distal colons (OR: 1.92, 95% CI: 1.01–3.35).
The relationship between size and pathological
features of the colorectal adenomas and MS was
not significant.
Discussion
Consistent with previous reports, this study con-
firms that subjects with MS have an increased risk
of colorectal adenoma.13,14 Separate analysis of the
components of MS showed that only abdominal
obesity was positively associated with the devel-
opment of colorectal adenoma. The OR for devel-
oping colorectal adenoma increases in a dependent
manner with the number of MS components. In
various combinations of the MS components, the
number-dependent phenomenon exists and ab-
dominal obesity showed consistency in the signifi-
cant group. MS was also associated significantly
with multiple and synchronous adenomas.
Insulin resistance is the major underlying
mechanism of MS and is hypothesized to play an
important role in the carcinogenesis of colorectal
cancer.15 Insulin itself is a powerful mitogenic
agent that has direct in vitro growth-promoting
effects.16,17 In addition, insulin directly activates
IGF-1, which stimulates the proliferation of
Table 1. Physical characteristics of the study population (n = 3106)
Characteristics Control (n = 2709)a Case (n = 397)a pb
Age (yr) 46.47 ± 10.53 51.54 ± 11.46 < 0.001
Sex (male/female) 1521/1188 303/94 < 0.001
Waist circumference (cm) 83.05 ± 9.11 86.73 ± 9.24 < 0.001
FBG (mg/dL) 93.57 ± 25.30 98.52 ± 28.10 0.001
Triglyceride (mg/dL) 131.91 ± 101.32 156.76 ± 102.13 < 0.001
Systolic BP (mmHg) 117.19 ± 19.17 123.34 ± 19.94 < 0.001
Diastolic BP (mmHg) 70.80 ± 11.50 74.27 ± 11.16 < 0.001
HDL-C (mg/dL) 55.23 ± 15.61 51.98 ± 16.75 < 0.001
Smoking
Current smoker (%) 23.03 41.81 < 0.001
Ex-smoker (%) 3.88 6.30 < 0.001
Alcohol drinking (%) 26.82 30.63 0.190
Past history of adenoma (%) 1.88 5.04 < 0.001
aData presented as mean ± standard deviation (for quantitative variables) or n (%) (for categorized variables); btwo-sample Student’s
t test for continuous variables and c2 test for categorical variables. HDL-C = high-density lipoprotein–cholesterol.
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colonic epithelium.18,19 However, measurement
of insulin resistance is not easy and generally not
part of the definition of MS for clinical purposes.
Abdominal obesity, hyperglycemia, dyslipidemia,
and elevated blood pressure are common mani-
festations of insulin resistance. Many studies have
been conducted on the association between colo-
rectal cancer and clinical manifestations of in-
sulin resistance.20,21 Nevertheless, studies of the
effect on colorectal adenoma have been limited,
with controversial results.22,23
In the present study, only abdominal obesity
was associated with colorectal adenoma (OR:
1.64, 95% CI: 1.30–2.07). In studies that con-
sider anthropometric measures of adipose tissue
distribution, the association between waist circum-
ference and colon adenoma or cancer has generally
been consistent.13,24 Abdominal obesity reflects
visceral fat deposition, which is associated with
insulin resistance and higher levels of circulating
IGF-1.25 Of the association with colorectal ade-
noma or cancer, studies have shown a stronger
association with abdominal obesity than general
obesity.3,26
Another reason for the link between MS and
colorectal adenoma could be chronic inflamma-
tion. Although chronic inflammation is believed
to be a predisposing factor for colon cancer,27 the
exact mechanisms that link these conditions 
remain unresolved. Chronic inflammation asso-
ciated with metabolic component involves a 
network of cellular and systemic responses that in-
tegrate many signaling pathways. Tumor necrosis
factor-α and interleukin-6, the well-known pro-
inflammatory cytokines, are some of the mediators
of these pathways.28 Increased adiposity is associ-
ated with infiltration of inflammatory cells and ab-
normal pro-inflammatory cytokine production.29
CRP is an objective marker of inflammation and
has been positively correlated with an increased
risk of colorectal neoplasia or adenoma in recent
studies.9,30 The so-called meta-inflammation
(metabolic inflammation) increases oxidative
stress, which leads to insulin resistance, elevated
blood pressure, and impaired plasma glucose.31
The CRP level is higher in MS subjects, which
suggests that inflammation is linked to insulin
resistance.9,32 The correlation between abdominal
Table 3. Risk factors in relation to the presence of metabolic syndrome in the adenoma group after adjustments
for age, sex, smoking, drinking and past history of adenoma
Adenoma MS+ (n = 132) MS− (n = 265) Adjusted OR 
p
characteristics n (%) n (%) (95% CI)
Location
Distal 23 (17) 45 (17) 1
Proximal 77 (58) 183 (69) 1.16 (0.64–2.09) 0.63
Both 32 (25) 37 (12) 1.92 (1.01–3.35) 0.02a
Number
Single 61 (46) 164 (62) 1
Multiple 71 (54) 101 (38) 1.67 (1.08–2.59) 0.02a
Size (cm)
< 0.5 61 (46) 112 (42) 1
0.5–1.0 59 (45) 141 (53) 0.78 (0.50–1.21) 0.27
> 1.0 12 (9) 12 (5) 1.62 (0.67–3.93) 0.28
Pathology
Non-advanced 99 (75) 213 (80) 1
Advanced 33 (25) 52 (20) 1.38 (0.80–2.30) 0.22
aSignificant difference, p < 0.05. MS = metabolic syndrome; OR = odds ratio; CI = confidence interval.
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obesity and colorectal adenoma observed in the
present study confirms the hypothesis.
Furthermore, the present study demonstrates
a dependent relationship between the number of
MS components and colorectal adenoma. As we
divided various MS component combinations into
average-, moderate-, and high-risk groups, the trend
was obvious when more aberrant MS components
and abdominal obesity existed. This suggests that
the sum of MS components represents a milieu
that promotes colorectal adenoma and that any
adenoma-promoting effects might be enhanced
by the presence of more MS components. Previous
studies have proposed that individuals with more
metabolic derangements are more likely to have
insulin resistance and/or hyperinsulinemia.13,33
The phenomenon that abdominal obesity appears
in different combinations with the MS components
further links insulin resistance, meta-inflammation,
and growth of colorectal adenomas.
In the present study, current smokers have 
a 2.37-fold higher risk of developing colorectal
adenoma, which is consistent with previous
studies.34,35 The risk of colorectal adenomas for
ex-smokers who have quit smoking for at least 
1 year is lower than for current smokers but is not
significantly different from that of non-smokers.
This finding suggests that cessation of cigarette
smoking has benefits for prevention of colorectal
adenoma formation, but the actual effect needs
to be confirmed by more studies.
The present study examined the association
between MS and the characteristics of colorectal
adenoma. The results reveal that MS leads to in-
creased risk of multiple adenomas and lesions 
in the proximal and distal colon, which reflects
that the meta-inflammation effect on insulin re-
sistance is systemic and induces multiple cellular
alterations without site specificity. However, there
is no significant association between size and
histological features between adenomas, which
might be due to the multifactorial adenoma–
carcinoma sequences and cannot be explained
by a single mechanism.
There were several limitations to the present
study. First, the study design was cross-sectional,
but for better determination of causality between
MS and colorectal adenoma, prospective studies
will be needed. Second, the family history of colo-
rectal cancer, which could be a weighted risk factor
for colorectal carcinogenesis, was incomplete and
not included due to recall bias and missing records.
Third, the total amount of daily smoking was not
quantified, and the physical activity status was
inaccurately recorded. Furthermore, with regard
to the measurement of insulin resistance, data re-
garding the insulin homeostatic model assessment,
such as CRP, leptin, or adiponectin, were lacking.
In summary, this study shows that MS subjects
have increased risk of colorectal adenoma, and
this increases with the number of MS components.
The number-dependent relationship confirms
the effect of insulin resistance on the prevalence
of colorectal adenoma. Of the individual MS
components, abdominal obesity is the most pre-
dominant predictor for colorectal adenoma.
Subjects with abdominal obesity might consider
receiving colonoscopy screening for colorectal
adenoma. MS should be considered as an impor-
tant risk factor for developing colorectal ade-
noma, especially when abdominal obesity or
more than three components of MS are present.
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